A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN).

Daniel M. Geynisman,Philip Abbosh,Eric A. Ross,Matthew R. Zibelman,Pooja Ghatalia,Fern Anari,Katherine Ansel,James Ryan Mark,Lambros Stamatakis, Jean H. Hoffman-Censits,Rosalia Viterbo,Eric M. Horwitz,Mark A. Hallman,R. Katherine Alpaugh,Richard E. Greenberg,Marc C. Smaldone,Robert Uzzo,David Chen,Alexander Kutikov,Elizabeth R. Plimack

JOURNAL OF CLINICAL ONCOLOGY（2023）

引用 25|浏览15

暂无评分

摘要

397Background: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy (Cx) or chemoradiation (CRT) is the standard of care for urothelial carcinoma (UC) pts with muscle invasive blad...

查看译文

关键词

bladder cancer,neoadjuvant chemotherapy,phase ii trial,risk-enabled

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要